Latanoprost Viatris (Latanoprost)

Latanoprost is a prostaglandin F (FP) receptor agonist. After topical application, it binds to FP receptors in the eye, promoting remodeling of the extracellular matrix and increasing uveoscleral outflow of aqueous humor, which lowers intraocular pressure.

The dosing regimen for Latanoprost is determined by the prescribing clinician. Typically, one drop is instilled in the affected eye(s) once daily in the evening, but the exact dose and timing should follow the prescriber’s instructions.

Safety data for Latanoprost in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and to discontinue breastfeeding while using the medication, unless advised otherwise by a healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which is often first‑line due to its once‑daily dosing and strong intraocular pressure‑lowering effect. Compared with beta‑blockers or carbonic anhydrase inhibitors, prostaglandin analogs typically achieve greater pressure reduction with a favorable dosing schedule.

Latanoprost eye drops should be stored at room temperature, away from direct sunlight and moisture. Keep the bottle tightly closed when not in use and retain it in the original packaging to protect the solution from contamination.

Latanoprost is administered as a single drop placed in the conjunctival sac of the affected eye(s) once daily, usually in the evening. Patients should wash their hands before use, avoid touching the tip of the bottle to any surface, and wait a few minutes before applying other eye medications.

Serious but rare risks include uveitis (inflammation of the uveal tract), corneal edema (swelling of the cornea), and sudden vision loss. Patients should seek immediate medical attention if they experience severe eye pain, redness, blurred vision, or any sudden change in visual acuity.

Latanoprost is contraindicated in individuals with known hypersensitivity to prostaglandin analogs or any component of the formulation. Caution is also advised for patients with active ocular inflammation, recent ocular surgery, or those who are pregnant or breastfeeding without clear medical justification.